Business
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions) Up to additional $20M in milestone and other future payments Future Pak becomes exclusive U.S. marketer for Mytesi® and Canalevia®-CA1 ...
About this update from Jaguar Health, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions)","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Up to additional $20M in milestone and other future payments","length":60,"tagName":"p"}]},{"val":[{"type":"text","content":"Future Pak becomes exclusive U.S. marketer for Mytesi® and Canalevia®-CA1","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"Jaguar continues to be the manufacturer of Mytesi and Canalevia-CA1","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Meaningful non-dilutive capital enables Jaguar to focus on its rare-disease pipeline, which is the subject of ongoing BD discussions with other potential partners","length":162,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":484,"olType":false},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / January 12, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that its wholly-owned subsidiary Napo Pharmaceuticals, Inc. (collectively, with Jaguar Health, Inc., "Jaguar") has entered into a U.S. licensing agreement with an affiliate of privately held Future Pak, LLC ("Future Pak"). Under the terms of the agreement, Future Pak will be the exclusive marketer for Mytesi (crofelemer), Jaguar's FDA-approved novel prescription drug for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, and Canalevia-CA1, Jaguar's crofelemer prescription drug for the treatment of chemotherapy-induced diarrhea in dogs. Jaguar will receive an $18 million upfront fee ($16 million at deal closing and $2 million upon completion of post-closing conditions) and up to $20 million in milestone payments and other future payments. Jaguar will continue to manufacture Mytesi and Canalevia-CA1 for Future Pak.","length":1016,"tagName":"p"},{"type":"text","content":"In September 2025, Future Pak acquired Theratechnologies Inc., a specialty biopharmaceutical company with two commercialized HIV medicines in the United States - EGRIFTA WR™ (tesamorelin) and Trogarzo® (ibalizumab-uiyk). "Jaguar's license arrangement with Future Pak represents a strategic convergence for heightening awareness of Mytesi and the importance of supportive care for HIV long...